Why Strategic Data Partnerships are the New Currency of Life Science Research Innovation
Published on: 20 Jan 2020
Last updated: 7 Apr 2026
Listen to audio summary of this article
The life sciences industry is currently navigating a paradox of plenty. While we have entered an era of unprecedented technological progress, driven by AI, machine learning, and high-throughput sequencing, the path to breakthrough treatments is more congested than ever.
Scientists estimate that the amount of healthcare data now doubles every 73 days. By 2050, we expect to have sequenced as many as 2 billion human genomes.
Jack Schmidt, director, life science industry practice, Deloitte, noted that “data is the new currency of life sciences innovation. From sequencing the genome to precision in personalised medicine to using technologies like artificial intelligence and machine learning to speed diagnostics…it’s truly revolutionary.”
However, like any currency, its value is zero if it cannot be spent or circulated. For many pharmaceutical and biotech firms, this "currency" is currently locked in unstructured silos, hampered by poor access and quality issues.
To unlock the next generation of precision medicine, the industry must undergo a fundamental structural shift: moving away from transactional, short-term vendor relationships toward strategic, long-term partnerships with specialised functional-service-provider firms.
The Failure of the Transactional Model
For decades, outsourcing in life sciences was treated as a "commodity purchase." A company had a surplus of data to clean or a specific regulatory report to write, so they hired a vendor for a one-off project. This transactional model is increasingly failing in the modern R&D landscape for three reasons:
The Context Gap: Short-term vendors lack the deep institutional knowledge of a drug’s lifecycle. They see a dataset, not the patient story or the long-term regulatory strategy behind it.
Inconsistent Quality: Switching vendors frequently leads to "data drift," where varying standards of validation make it impossible to perform longitudinal meta-analysis across multiple trials.
The Innovation Bottleneck: Transactional relationships focus on "checking the box" rather than improving the process. There is no incentive for a short-term vendor to suggest architectural improvements that could speed up the next trial.
The Strategic Alternative: The FSP Partnership
The good news is, functional-service-providers, and life science KPO firms can partner to help make this data more accessible for researchers, which could result in new drugs and cures delivered faster. Clients will be able to quickly access information when and where it’s needed most, and in a format that’s structured and actionable.
Clinical trials are the bedrock that supports the development of new treatments and products, and more data will only make them stronger. Secondly, medical writing, like regulatory as well as educational material and clinical research documents, are quite critical to pharma operations because regulatory agencies have adopted more elaborate review measures that require substantial documentation.
Life science firms can rely on strategic long-term partnerships with data service firms for data research, medical writing, and insights to gain access to a deep database of patient claims data, and intelligence to make better decisions. This will not only help in clinical trials but also in launching products, streamline the supply chain, and improve time-to-market.
Maintaining close relationships with vendors will be critical for compliant operations, because an oversight may cost pharma companies their reputation.
Strategic Outsourcing with Ascentrik Research
The evolution toward Strategic, Relationship-Based Outsourcing represents a move from "buying hours" to "investing in outcomes." When a life science firm enters a long-term alliance with a specialised partner like Ascentrik Research, the relationship transforms into a "Functional Service Provider" (FSP) model.
1. Bridging the "Translational" Gap
The ability to improve the bi-directional learning between the patient and the drug discovery process is the central strategy of this decade. However, poor data access often halts this flow.
A strategic partner doesn't just "process" data; they build the governance and architecture that allow researchers to access key datasets faster and more efficiently. This turns raw biological information into actionable insights that can mitigate risks early in the clinical cycle.
2. Maintaining the "Gold Standard" of Compliance
In an era where regulatory agencies have adopted more elaborate review measures, oversight is not just an inconvenience—it is a reputational and financial disaster. Strategic partners integrate deeply into a firm’s Quality Management Systems (QMS).
Over time, the partner develops a "muscle memory" for the specific compliance nuances of the sponsor, ensuring that every manuscript, regulatory submission, and clinical document is "audit-ready" from day one.
3. Powering Precision Through Specialist Expertise
Non-core activities—such as scientific data mining, bioinformatics, and medical coding—require highly specialised talent that is difficult to retain in-house.
A long-term data partner provides a "deep bench" of MDs, PhDs, and data scientists who function as an extension of the internal team. This allows the pharma giant to remain lean and focus on their core competency: Scientific Discovery.
How Data Partnerships Accelerate the Value Chain
The impact of moving to a partnership-driven research model is felt across the entire organisation:
Clinical Trials: High-quality, validated data becomes the bedrock for stronger trials, allowing for more targeted therapies and higher clinical success rates.
Supply Chain & Logistics: Advanced analytics provided by a data partner can help optimise logistics, especially for the complex distribution requirements of biologics and personalised medicines.
Sales & Marketing: Beyond the lab, real-world data (RWD) and competitive intelligence allow marketing teams to identify trends and reach the right HCPs with surgical precision.
Conclusion: Turning Data Proliferation into Decision-Making
The future of life sciences innovation will not be won by the company with the most data, but by the company that can decide the fastest. Data proliferation is only a benefit if it aids in decision-making.
By fostering relationship-driven partnerships with outsourcing vendors, life science firms can finally remove the barriers to collaboration. These alliances provide the structure, the validation, and the specialised intelligence needed to turn a "mountain of data" into a "map for discovery."
The shift to strategic outsourcing is no longer just a cost-control measure—it is the essential architecture for the future of human health.
Ascentrik Research is uniquely positioned to be your extended team for secondary data support services in healthcare data research. Our emphasis on customised services and human-driven research ensures that the data you receive is not just information, but a strategic asset.
By partnering with us, you gain access to niche, high-quality, and current data that directly integrates with your existing products, offering a powerful advantage in the competitive landscape of healthcare data products.
